dc.contributor.author
Hernández-Hernández, Elena
dc.contributor.author
Ledesma-Corvi, Sandra
dc.contributor.author
Yáñez-Gómez, Fernando
dc.contributor.author
Garau, Celia
dc.contributor.author
Gálvez-Melero, Laura
dc.contributor.author
Bagán Polonio, Andrea
dc.contributor.author
Escolano Mirón, Carmen
dc.contributor.author
García-Fuster, M. Julia
dc.date.issued
2023-05-04T09:04:04Z
dc.date.issued
2023-05-04T09:04:04Z
dc.date.issued
2023-02-11
dc.date.issued
2023-05-04T09:04:04Z
dc.identifier
https://hdl.handle.net/2445/197543
dc.description.abstract
In searching for novel targets to design antidepressants, among the characterized imidazoline receptors (IR), I2 receptors are an innovative therapeutical approach since they are dysregulated in major depressive disorder and by classical antidepressant treatments. In fact, several I2 agonists have been characterized for their antidepressant-like potential, but the results in terms of efficacy were mixed and exclusively reported in male rodents. Since there are well-known sex differences in antidepressant-like efficacy, this study characterized the potential effects induced by two I2 drugs, CR4056 (i.e., most promising drug already in phase II clinical trial for its analgesic properties) and B06 (a compound from a new family of bicyclic α-iminophosphonates) under the stress of the forced-swim test in male and female rats exposed to early-life stress. Moreover, some hippocampal neuroplasticity markers related to the potential effects observed were also evaluated (i.e., FADD, p-ERK/ERK, mBDNF, cell proliferation: Ki-67 + cells). The main results replicated the only prior study reporting the efficacy of CR4056 in male rats, while providing new data on its efficacy in females, which was clearly dependent on prior early-life stress exposure. Moreover, B06 showed no antidepressant-like effects in male or female rats. Finally, CR4056 increased FADD content and decreased cell proliferation in hippocampus, without affecting p- ERK/t-ERK ratio and/or mBDNF content. Interestingly, these effects were exclusively observed in female rats, and independently of early-life conditions, suggesting some distinctive molecular underpinnings participating in the therapeutic response of CR4056 for both sexes. In conjunction, these results present CR4056 with an antidepressant-like potential, especially in female rats exposed to stress early in life, together with some neuronal correlates described in the context of these behavioral changes in females.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Elsevier B.V.
dc.relation
Reproducció del document publicat a: https://doi.org/10.1016/j.pbb.2023.173527
dc.relation
Pharmacology Biochemistry and Behavior, 2023, vol. 223, p. 173527
dc.relation
https://doi.org/10.1016/j.pbb.2023.173527
dc.rights
cc-by (c) Elena Hernández-Hernández, et al., 2023
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Depressió psíquica
dc.subject
Hipocamp (Cervell)
dc.subject
Mental depression
dc.subject
Hippocampus (Brain)
dc.title
Sex differences in the antidepressant-like response and molecular events induced by the imidazoline-2 receptor agonist CR4056 in rats
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion